Leo Pharma Wins Dismissal of Suit Over Withdrawn Picato Skin Gel

Leo Pharma Inc. and its Danish parent Leo Pharma A/S won dismissal, for now, of a proposed class suit alleging its withdrawn skin treatment Picato posed an unreasonably high risk of skin cancer, as a federal court in California said he failed to allege his doctor wasn’t adequately warned.

Brian Kamlade’s doctor prescribed Picato in July 2018 to treat precancerous Actinic Keratosis, a scaly lesion on the skin caused by excessive sunlight exposure. Kamlade said he developed skin cancer in the treatment area.

European and Canadian health authorities found a possible link between Picato and skin cancer, Kamlade said, and ...